Revenue
2022
2023
2024
2025
Sagimet Biosciences Inc. (SGMT)
Price$10.94Cached quote
Net income
2022
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $2.0M | $0 |
| Research & development | $39.1M | $38.4M | $19.8M | $24.9M |
| Operating expenses | $56.9M | $54.5M | $32.7M | $31.1M |
| Operating income | −$56.9M | −$54.5M | −$30.7M | −$31.1M |
| Operating margin | — | — | −1,537.00% | — |
| EBITDA | −$56.9M | −$54.5M | −$30.7M | −$31.1M |
| EBITDA margin | — | — | −1,537.00% | — |
| Net income | −$51.0M | −$45.6M | −$27.9M | −$30.5M |
| Net profit margin | — | — | −1,393.80% | — |
| Basic EPSper basic share | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
| Diluted EPSper diluted share | -$1.58 | -$1.45 | -$2.66 | -$165.20 |
Owners
Reported shareholders
10.74%of listed shares
BlackRock, Inc.6.58M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | 10.74%6.58M shares |
Balyasny Asset Management L.P. | 5.92%3.63M shares |
Woodline Partners LP | 4.90%3M shares |
SILVERARC CAPITAL MANAGEMENT, LLC | 4.78%2.93M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.19%2.57M shares |
BVF INC/IL | 4.08%2.5M shares |
Caligan Partners LP | 4.08%2.5M shares |
Affinity Asset Advisors, LLC | 4.08%2.5M shares |
FEDERATED HERMES, INC. | 3.41%2.09M shares |
GREAT POINT PARTNERS LLC | 3.32%2.03M shares |
STATE STREET CORP | 3.26%2M shares |
Saturn V Capital Management LP | 2.42%1.48M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.36%1.44M shares |
Blue Owl Capital Holdings LP | 2.06%1.26M shares |
BAKER BROS. ADVISORS LP | 1.56%953K shares |
MILLENNIUM MANAGEMENT LLC | 1.53%937.03K shares |
Aberdeen Group plc | 1.38%847.7K shares |
Happel David | ≈1.32%805.62K shares |
GOLDMAN SACHS GROUP INC | 1.24%759.09K shares |
HHLR ADVISORS, LTD. | 1.18%724.8K shares |
Percentages use 61.22M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 10, 2026Form 4 | Happel DavidPresident & CEO | SellSeries A Common Stock | 12.1K | $5.36 | $64.9K | 677.6K |
| Feb 10, 2026Form 4 | Chauche ThierryChief Financial Officer | SellSeries A Common Stock | 1.3K | $5.36 | $7.0K | 15.7K |
| Feb 10, 2026Form 4 | Martins Eduardo BrunoChief Medical Officer | SellSeries A Common Stock | 3.6K | $5.36 | $19.5K | 103.3K |
| Feb 10, 2026Form 4 | Rozek ElizabethChief Legal & Admin. Officer | SellSeries A Common Stock | 2.6K | $5.36 | $14.1K | 191.0K |
| Nov 20, 2025Form 4 · 10b5-1 | Kemble GeorgeExecutive Chairman | SellSeries A Common Stock | 37.7K | $7.69 | $289.8K | 81.0K |